Welcome to our dedicated page for Braxia Scientifi news (Ticker: BRAXF), a resource for investors and traders seeking the latest updates and insights on Braxia Scientifi stock.
Braxia Scientific Corp. (BRAXF) is a medical research leader developing ketamine-based therapies and psychedelic treatments for mental health disorders through its clinical network and telemedicine platform. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's scientific advancements, regulatory milestones, and operational developments.
Access official press releases covering clinical trial results, partnership announcements, financial disclosures, and technology innovations like the KetaMD platform. Our curated news collection enables efficient tracking of Braxia's progress in transforming depression treatment through rapid-acting therapies and novel drug delivery systems.
Key content includes updates on multidisciplinary clinic operations, research publications, intellectual property developments, and management strategy changes. All materials are sourced directly from company filings and verified industry publications to ensure reliability.
Bookmark this page for consolidated access to Braxia Scientific's evolving role in mental health innovation. Check regularly for updates on telemedicine expansion, treatment protocol refinements, and strategic initiatives in the competitive psychedelic therapy sector.
Braxia Scientific Corp. announced the voting results from its Annual General Meeting held on October 28, 2021, where 11.77% of shares were represented. Four nominees were elected as Directors, with Roger McIntyre receiving 96.13% approval, Jerry Habuda 84.91%, Olga Cwiek 86.75%, and David Greenberg 86.89%. Additionally, shareholders approved the appointment of DMCL as auditors for the following year. Braxia focuses on innovative ketamine treatments for depression and aims to reduce the burden of mental disorders through its clinics and research.
Braxia Scientific Corp. has announced updated details for its annual general meeting scheduled for October 28, 2021, at 10:00 am (ET). Changes include new audio webcast and dial-in information for shareholders. Braxia Scientific focuses on innovative ketamine treatments for depression and related disorders, operating clinics in Mississauga, Toronto, Ottawa, and Montreal. The company aims to reduce the burden of mental disorders and is engaged in developing novel drugs and delivery methods.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) is gaining media attention for its innovative ketamine treatments for depression. CEO Dr. Roger McIntyre is set to appear on CTV's W5 on October 23, 2021, discussing 'Psychedelic Healing'. The company was also featured in a Toronto Life article, highlighting ketamine's rapid effectiveness in treating mental disorders. Braxia operates clinics in major Canadian cities, aiming to alleviate the burden of brain-based mental illnesses.
Braxia Scientific Corp. announced the publication of a study in the Journal of the Royal Society of Medicine, led by CEO Dr. Roger McIntyre, focusing on suicide reduction in Canada during the COVID-19 pandemic. The study highlights a decrease in the suicide mortality rate from 10.82 to 7.34 per 100,000, attributing the decline to increased access to virtual psychiatric care. Braxia aims to further reduce suicidality through ketamine treatments and potential derivatives, emphasizing the importance of public policies prioritizing psychiatric services.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced encouraging preliminary findings from a clinical study suggesting that ketamine is effective as a standalone antidepressant for treatment-resistant depression (TRD). Conducted at the Canadian Rapid Treatment Centre of Excellence, the study involved 220 patients. Participants receiving intravenous (IV) ketamine monotherapy had response and remission rates of 39.1% and 17.4%, significantly outperforming those on adjunctive treatments. These results indicate ketamine's potential as a primary treatment option, impacting Braxia's drug discovery efforts.
Braxia Scientific Corp. reported a significant 80.3% revenue increase, reaching $407,075 for Q1 fiscal 2021. The company has exceeded its monthly IV Ketamine infusion targets, particularly at its new clinic in Montreal. Additionally, Braxia is advancing three funded clinical trials, including groundbreaking studies on ketamine and psilocybin for treating depression. Despite these gains, the company recorded a net loss of $1,091,568, influenced by share-based compensation expenses.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company, focused on innovative ketamine treatments for depression, also disclosed the issuance of 200,000 common shares valued at $62,000 to settle payments to an independent medical advisor. Braxia operates clinics across Canada and aims to transform mental health treatment. Forward-looking statements indicate potential risks related to regulatory approvals and treatment efficacy.
Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation in the virtual Canaccord Genuity Annual Growth Conference, scheduled for August 10-12, 2021. CEO Dr. Roger McIntyre will present the company's initiatives focusing on novel therapeutics for depression and brain-based disorders. The presentation is set for August 10 at 11:30 a.m. ET. Braxia operates clinics providing ketamine treatments for mental health issues and is engaged in developing new drugs and delivery systems while striving to alleviate the burden of mental disorders.
Braxia Scientific Corp. reported its fiscal fourth-quarter and year-end results for the period ending March 31, 2021. The company generated revenues of $1,008,372 for the year, with a gross margin of $145,666. Major losses of $88,828,146 were primarily driven by a non-cash listing expense. Braxia expanded its clinic network to four locations in Canada and established direct billing with a health insurance provider for veterans. The company is advancing multiple clinical trials and initiatives in ketamine-assisted therapy while enhancing its management team.
Braxia Scientific Corp. has received $918,000 in funding from the Canadian Institutes of Health Research to investigate the efficacy of combining intravenous ketamine with internet-based cognitive behavioral therapy (iCBT) to reduce suicidality in individuals with depression. The clinical trial, ranked in the 94th percentile by CIHR, will be conducted in Mississauga and at other locations in Canada. Suicidality is a significant public health issue, being the second-leading cause of death among youth and young adults in Canada.
